Renaissance Technologies LLC Reduces Position in Personalis, Inc. $PSNL

Renaissance Technologies LLC decreased its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 83.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,200 shares of the company’s stock after selling 77,794 shares during the period. Renaissance Technologies LLC’s holdings in Personalis were worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc purchased a new position in Personalis during the second quarter valued at $30,000. International Assets Investment Management LLC purchased a new position in Personalis during the fourth quarter valued at $31,000. BNP Paribas Financial Markets grew its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Finally, Focus Partners Wealth bought a new stake in Personalis during the first quarter valued at about $47,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Zacks Research lowered shares of Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. BTIG Research raised their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a research note on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $14.25.

Insider Buying and Selling

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. The trade was a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by insiders.

Personalis Stock Performance

Shares of PSNL stock opened at $16.88 on Friday. The stock has a fifty day simple moving average of $13.12 and a two-hundred day simple moving average of $9.62. The firm has a market capitalization of $1.77 billion, a PE ratio of -15.49 and a beta of 2.27. Personalis, Inc. has a 52-week low of $4.59 and a 52-week high of $17.06.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. On average, sell-side analysts forecast that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.